- Five presentations affirm positive outcomes utilizing inhaled insulin
- An sNDA filing for Afrezza in pediatric population anticipated in 2025
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 10, 2025 (GLOBE NEWSWIRE) — MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, will showcase data from recent studies of inhaled insulin across five presentations at the 18th International Conference on Advanced Technologies and Treatments for Diabetes to be held March 19-22 in Amsterdam.
“Data from both the INHALE-1 pediatric and INHALE-3 adult studies continue to drive groundbreaking conversations around inhaled insulin,” said Dr. Kevin Kaiserman, Senior Vice President, Therapeutic Area Head, Endocrine Diseases for MannKind Corporation. “Afrezza continues to be an important treatment option for adults living with diabetes, including those utilizing MDI and AID, and we look forward to the study investigators’ presentations at the ATTD meeting.”
The following oral presentations are on the scientific program at ATTD 2025 to be held virtually and at the RAI Amsterdam Convention Center:
What’s New in Pulmonary Inhaled Insulin?
Thursday, March 20, 2025 – 4:40 PM (CET) in Hall I
Presenter: Dr. Irl B. Hirsch
Inhaled Insulin in Pediatrics (INHALE-1 Peds Study)
Thursday, March 20, 2025 – 4:40 PM (CET) in Hall I
Presenter: Dr. Michael J. Haller
Sustained Benefit from Use of Inhaled Insulin in the INHALE-3 Extension Study
Saturday, March 22, 2025 – 11:05 AM (CET) at Station 4
Presenter: Dr. Grazia Aleppo
Post-Prandial Glucose Excursion with Inhaled Insulin in Youth Compared with Adults with Type 1 Diabetes (INHALE-1 Peds Study)
Saturday, March 22, 2025 – 11:30 AM (CET) in Hall D2
Presenter: Dr. Michael J. Haller
Comparison of a Regimen of Inhaled Technosphere Insulin Plus Insulin Degludec Versus Usual Care in Adults with Type 1 Diabetes
Saturday, March 22, 2025 – 11:30 AM (CET) in Hall D2
Presenter: Dr. Anastasios Manessis
In addition to the planned presentations, MannKind will host booth #40 in the exhibit hall (Hall I) throughout ATTD. Members of MannKind’s Clinical Education Team will be available for scientific exchange in the medical section of the booth.
For more information about ATTD programming, and/or to register to attend the conference (virtual or in person), please visit: https://attd.kenes.com/register/.
About the INHALE-1 Pediatric Study
INHALE-1 is a Phase 3, randomized controlled trial in children and teenagers aged 4-17 with type 1 or type 2 diabetes to evaluate the efficacy and safety of inhaled insulin in combination with basal insulin versus multiple daily …
